Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial.
Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C and Linn T
01/01/2008
The Lancet,371 (9618), 1073-1084. View article here.